Abstract 366P
Background
Microbiome has been proposed as a promising prognostic biomarker in various types of cancer. Although recent microbiome studies have linked the bacterial microbiome in the oral cavity and nasopharynx to the prognosis of nasopharyngeal carcinoma (NPC), the clinical significance of oral mycobiome, another key player of the oral microbiome, in NPC survival remain unknown.
Methods
We enrolled 476 untreated incident NPC patients from Wuzhou, southern China during March 2010 and December 2013, with follow-up through December 2018. We collected saliva samples at the time of diagnosis and characterized the oral mycobiome using fungal internal transcribed spacer (ITS)-2 sequencing. We analyzed the relationship between oral mycobiome and the overall survival using Cox regression adjusting for multiple confounders.
Results
Overall, the average follow-up of the NPC patients [mean (SD) age, 48.5 (10.7) years; 72% male) was 5.26 years. Patients with lower oral fungal alpha diversity (measured by observed features) had an inferior 5-year overall survival rate (lower group vs. higher group = 54.9% vs. 69.6%, P for log-rank test = 0.007). We found that lower alpha diversity was associated with an increased mortality [lower vs. higher: observed features (fully adjusted hazard ratio [HR] = 1.56, 95% confidence interval [CI] = 1.08-2.25); Simpson diversity (1.50, 1.04-2.15); Shannon diversity (1.79, 1.25-2.56)]. The associations were attenuated when further adjusted for cancer stage at diagnosis, and the significant associations were found only among localized-tumor-stage patients.
Conclusions
Oral mycobiome is a potential prognostic biomarker for patients with NPC and might provide potential guidance for treatment decision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The original field work was supported by a grant from the National Cancer Institute at the US National Institutes of Health (grant number: R01 CA115873). This work was supported by the Swedish Research Council (grant numbers: 2015-02625, 2015-06268, 2017-05814, 2019-01429), and the High-level Talents Research Start-up Project of Fujian Medical University (grant numbers: XRCZX2017035 and XRCZX2020034), the National Natural Science Foundation of China (grant number: U22A20322). Yufeng Chen was also partly supported by a scholarship from China Scholarship Council (grant number: 201600160071).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract